Sorafenib in metastatic radioactive iodine‑refractory differentiated thyroid cancer: A pilot study

Luo,Yang; Shi,Yuankai; Xing,Puyuan; Wang,Lin; Feng,Yun; Han,Xiaohong; He,Xiaohui

doi:10.3892/mco.2013.199

Sorafenib in metastatic radioactive iodine‑refractory differentiated thyroid cancer: A pilot study

Authors:
- Yang Luo
- Yuankai Shi
- Puyuan Xing
- Lin Wang
- Yun Feng
- Xiaohong Han
- Xiaohui He
View Affiliations

Affiliations: Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China
Published online on: October 9, 2013 https://doi.org/10.3892/mco.2013.199
Pages: 87-92

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

the incidence and mortality of thyroid cancer are on the increase worldwide and the treatment options for progressive, radioactive iodine (RAI)‑refractory metastatic differentiated thyroid cancer (DTC) patients are currently limited. Sorafenib is a multikinase inhibitor that targets several molecular signals, which are believed to be involved in the pathogenesis of DTC. In this study, we reported our experience with the off‑label use of sorafenib in Chinese cancer patients. A total of 8 patients (7 with papillary and 1 with follicular thyroid cancer) were recruited in this study. The partial response (PR) rate was 50.0% and 5 of the 8 patients (62.5%) achieved a durable response. The median progression‑free survival (PFS) and overall survival (OS) were 40.1 and 55.0 weeks, respectively. Lung metastases were more sensitive to sorafenib compared to lymph nodes. The tumor marker response was not in accordance with the radiological response, although patients with tumor marker complete response (CR) exhibited a longer PFS and OS compared to those without a CR. Common adverse events (AEs) included palmar‑plantar erythrodysesthesia, hypertension, diarrhea, weight loss and alopecia. Grade 4 AEs comprised hypocalcemia (1 patient) and elevated amylase levels (1 patient). A dose reduction was required in 62.5% of the patients. In conclusion, sorafenib exhibited a clinically relevant antitumor activity in patients with progressive metastatic RAI‑refractory DTC, although the majority of the patients required a dose reduction due to intolerable toxicity.

View Figures

View References

1.	Sherman SI: Thyroid carcinoma. Lancet. 361:501–511. 2003. View Article : Google Scholar : PubMed/NCBI
2.	Mazzaferri EL: An overview of the management of papillary and follicular thyroid carcinoma. Thyroid. 9:421–427. 1999. View Article : Google Scholar : PubMed/NCBI
3.	Jonklaas J, Sarlis NJ, Litofsky D, et al: Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 16:1229–1242. 2006. View Article : Google Scholar : PubMed/NCBI
4.	Sampson E, Brierley JD, Le LW, et al: Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer. 110:1451–1456. 2007. View Article : Google Scholar : PubMed/NCBI
5.	Shimaoka K, Schoenfeld DA, DeWys WD, et al: A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 56:2155–2160. 1985. View Article : Google Scholar : PubMed/NCBI
6.	Caronia LM, Phay JE and Shah MH: Role of BRAF in thyroid oncogenesis. Clin Cancer Res. 17:7511–7517. 2011. View Article : Google Scholar : PubMed/NCBI
7.	Cohen Y, Xing M, Mambo E, et al: BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 95:625–627. 2003. View Article : Google Scholar : PubMed/NCBI
8.	Henderson YC, Shellenberger TD, Williams MD, et al: High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res. 15:485–491. 2009. View Article : Google Scholar : PubMed/NCBI
9.	Antonelli A, Fallahi P, Ferrari SM, et al: New targeted therapies for thyroid cancer. Curr Genomics. 12:626–631. 2011. View Article : Google Scholar : PubMed/NCBI
10.	Gupta-Abramson V, Troxel AB, Nellore A, et al: Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 26:4714–4719. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Kloos RT, Ringel MD, Knopp MV, et al: Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 27:1675–1684. 2009. View Article : Google Scholar : PubMed/NCBI
12.	Hoftijzer H, Heemstra KA, Morreau H, et al: Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol. 161:923–931. 2009. View Article : Google Scholar : PubMed/NCBI
13.	Ahmed M, Barbachano Y, Riddell A, et al: Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol. 165:315–322. 2011. View Article : Google Scholar : PubMed/NCBI
14.	Wilhelm SM, Adnane L, Newell P, et al: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Garcia-Rostan G, Zhao H, Camp RL, et al: ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol. 21:3226–3235. 2003. View Article : Google Scholar : PubMed/NCBI
16.	Vieira JM, Santos SC, Espadinha C, et al: Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. Eur J Endocrinol. 153:701–709. 2005. View Article : Google Scholar : PubMed/NCBI
17.	Jo YS, Li S, Song JH, et al: Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab. 91:3667–3670. 2006. View Article : Google Scholar : PubMed/NCBI
18.	Schneider TC, Abdulrahman RM, Corssmit EP, et al: Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol. 167:643–650. 2012. View Article : Google Scholar
19.	Cabanillas ME, Waguespack SG, Bronstein Y, et al: Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab. 95:2588–2595. 2010. View Article : Google Scholar : PubMed/NCBI
20.	Cabanillas ME, Hu MI, Durand JB, et al: Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res. 2011:9857802011. View Article : Google Scholar : PubMed/NCBI
21.	Qiu ZL, Song HJ, Xu YH, et al: Efficacy and survival analysis of ¹³¹I therapy for bone metastases from differentiated thyroid cancer. J Clin Endocrinol Metab. 96:3078–3086. 2011.PubMed/NCBI